Hee Young Seok1, Jinghai Chen, Masaharu Kataoka, Zhan-Peng Huang, Jian Ding, Jinglu Yan, Xiaoyun Hu, Da-Zhi Wang. 1. From the Department of Cardiology, Boston Children's Hospital, Harvard Medical School, MA (H.Y.S., J.C., M.K., Z.-P.H., J.D., J.Y., X.H., D.-Z.W.); Program of Integrative Medicine, Department of Cardiology, Beijing University of Chinese Medicine, Beijing, China (J.Y.); and Harvard Stem Cell Institute, Harvard University, Cambridge, MA (D.-Z.W.).
Abstract
RATIONALE: In response to mechanical and pathological stress, adult mammalian hearts often undergo mal-remodeling, a process commonly characterized as pathological hypertrophy, which is associated with upregulation of fetal genes, increased fibrosis, and reduction of cardiac dysfunction. The molecular pathways that regulate this process are not fully understood. OBJECTIVE: To explore the function of microRNA-155 (miR-155) in cardiac hypertrophy and remodeling. METHODS AND RESULTS: Our previous work identified miR-155 as a critical microRNA that repressed the expression and function of the myocyte enhancer factor 2A. In this study, we found that miR-155 is expressed in cardiomyocytes and that its expression is reduced in pressure overload-induced hypertrophic hearts. In mouse models of cardiac hypertrophy, miR-155 null hearts suppressed cardiac hypertrophy and cardiac remodeling in response to 2 independent pathological stressors, transverse aortic restriction and an activated calcineurin transgene. Most importantly, loss of miR-155 prevents the progress of heart failure and substantially extends the survival of calcineurin transgenic mice. The function of miR-155 in hypertrophy is confirmed in isolated cardiomyocytes. We identified jumonji, AT rich interactive domain 2 (Jarid2) as an miR-155 target in the heart. miR-155 directly represses Jarid2, whose expression is increased in miR-155 null hearts. Inhibition of endogenous Jarid2 partially rescues the effect of miR-155 loss in isolated cardiomyocytes. CONCLUSIONS: Our studies uncover miR-155 as an inducer of pathological cardiomyocyte hypertrophy and suggest that inhibition of endogenous miR-155 might have clinical potential to suppress cardiac hypertrophy and heart failure.
RATIONALE: In response to mechanical and pathological stress, adult mammalian hearts often undergo mal-remodeling, a process commonly characterized as pathological hypertrophy, which is associated with upregulation of fetal genes, increased fibrosis, and reduction of cardiac dysfunction. The molecular pathways that regulate this process are not fully understood. OBJECTIVE: To explore the function of microRNA-155 (miR-155) in cardiac hypertrophy and remodeling. METHODS AND RESULTS: Our previous work identified miR-155 as a critical microRNA that repressed the expression and function of the myocyte enhancer factor 2A. In this study, we found that miR-155 is expressed in cardiomyocytes and that its expression is reduced in pressure overload-induced hypertrophic hearts. In mouse models of cardiac hypertrophy, miR-155 null hearts suppressed cardiac hypertrophy and cardiac remodeling in response to 2 independent pathological stressors, transverse aortic restriction and an activated calcineurin transgene. Most importantly, loss of miR-155 prevents the progress of heart failure and substantially extends the survival of calcineurin transgenic mice. The function of miR-155 in hypertrophy is confirmed in isolated cardiomyocytes. We identified jumonji, AT rich interactive domain 2 (Jarid2) as an miR-155 target in the heart. miR-155 directly represses Jarid2, whose expression is increased in miR-155 null hearts. Inhibition of endogenous Jarid2 partially rescues the effect of miR-155 loss in isolated cardiomyocytes. CONCLUSIONS: Our studies uncover miR-155 as an inducer of pathological cardiomyocyte hypertrophy and suggest that inhibition of endogenous miR-155 might have clinical potential to suppress cardiac hypertrophy and heart failure.
Authors: Sam Mattiske; Rachel J Suetani; Paul M Neilsen; David F Callen Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Hee Young Seok; Mariko Tatsuguchi; Thomas E Callis; Aibin He; William T Pu; Da-Zhi Wang Journal: J Biol Chem Date: 2011-08-25 Impact factor: 5.157
Authors: Maarten F Corsten; Anna Papageorgiou; Wouter Verhesen; Paolo Carai; Morten Lindow; Susanna Obad; Georg Summer; Susan L M Coort; Mark Hazebroek; Rick van Leeuwen; Marion J J Gijbels; Erwin Wijnands; Erik A L Biessen; Menno P J De Winther; Frank R M Stassen; Peter Carmeliet; Sakari Kauppinen; Blanche Schroen; Stephane Heymans Journal: Circ Res Date: 2012-06-19 Impact factor: 17.367
Authors: Gabriel B Loeb; Aly A Khan; David Canner; Joseph B Hiatt; Jay Shendure; Robert B Darnell; Christina S Leslie; Alexander Y Rudensky Journal: Mol Cell Date: 2012-11-08 Impact factor: 17.970
Authors: Jia Liu; Alain van Mil; Krijn Vrijsen; Jiajun Zhao; Ling Gao; Corina H G Metz; Marie-José Goumans; Pieter A Doevendans; Joost P G Sluijter Journal: J Cell Mol Med Date: 2010-06-09 Impact factor: 5.310
Authors: Anselm A Derda; Sabrina Thum; Johan M Lorenzen; Udo Bavendiek; Joerg Heineke; Britta Keyser; Manfred Stuhrmann; Raymond C Givens; Peter J Kennel; P Christian Schulze; Julian D Widder; Johann Bauersachs; Thomas Thum Journal: Int J Cardiol Date: 2015-06-05 Impact factor: 4.164
Authors: Connie Wu; Pankaj Arora; Obiajulu Agha; Liam A Hurst; Kaitlin Allen; Daniel I Nathan; Dongjian Hu; Pawina Jiramongkolchai; J Gustav Smith; Olle Melander; Sander Trenson; Stefan P Janssens; Ibrahim Domian; Thomas J Wang; Kenneth D Bloch; Emmanuel S Buys; Donald B Bloch; Christopher Newton-Cheh Journal: Mol Cell Biol Date: 2016-06-29 Impact factor: 4.272